FAQ: Soligenix CEO Presentation at H.C. Wainwright Global Investment Conference
Summary
Soligenix Inc. CEO Christopher J. Schaber will present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025, with the on-demand presentation available starting September 5th. This provides investors with insights into the company's late-stage biopharmaceutical developments for rare diseases and public health solutions.
What is the main topic of this announcement?
Soligenix Inc. announced that President and CEO Christopher J. Schaber, Ph.D., will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, providing updates on the company’s biopharmaceutical developments.
When and where is the H.C. Wainwright conference taking place?
The conference is taking place September 8-10, 2025, with the on-demand presentation available beginning September 5 at 7 a.m. ET through the conference platform.
Who is presenting for Soligenix at the conference?
President and CEO Christopher J. Schaber, Ph.D., will deliver the corporate presentation, and Soligenix management will also participate in one-on-one meetings during the event.
What type of company is Soligenix and what do they focus on?
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, with two main business segments: Specialized BioTherapeutics and Public Health Solutions.
What are Soligenix’s main development programs?
The company is developing HyBryte™ for cutaneous T-cell lymphoma, synthetic hypericin for psoriasis, dusquetide for inflammatory diseases, and vaccine programs including RiVax® for ricin toxin, filovirus vaccines, and CiVax™ for COVID-19 prevention.
How is Soligenix’s public health solutions segment funded?
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Where can investors find more information about Soligenix?
The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX, and the full press release can be viewed at https://ibn.fm/DkBRA.
What is the significance of this conference presentation for investors?
The presentation provides investors with important updates on Soligenix’s late-stage developments and commercialization progress, particularly for HyBryte™ which has completed Phase 3 studies and is moving toward potential regulatory approvals worldwide.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 192270